Lottery.com Inc
Change company Symbol lookup
Select an option...
LTRY Lottery.com Inc
RCLF Rosecliff Acquisition Corp I
SSYS Stratasys Ltd
GRN iPath? Series B Carbon ETN
RCKTF Rock Tech Lithium Inc
SOND Sonder Holdings Inc
PTE PolarityTE Inc
CTRA Coterra Energy Inc
L Loews Corp
HSY Hershey Co
Go

*Nasdaq FSI: *Deficient and Delinquent: Issuer Failed to Meet NASDAQ Continued Listing Requirements, and Missed Regulatory Filing Deadline

Company profile

Lottery.com Inc. is a technology company that is a provider of domestic and international lottery products and services. It is engaged in mobile and online platforms that enable players located in the United States and internationally to remotely purchase legally sanctioned lottery games. The Company offers the platform through the Lottery.com app and its Websites to users located in the United States. and international jurisdictions where the sale of lottery games is legal, and its services are enabled for the remote purchase of legally sanctioned lottery games (B2C Platform). It offers an internally developed, created and operated business-to-business application programming interface (API) of the platform to enable commercial partners in permitted the United States and international jurisdictions to purchase certain legally operated lottery games from the Company and resell them to users located within their respective jurisdictions (B2B API). It also delivers global lottery data.

Price
Delayed
$0.2581
Day's Change
0.019 (7.95%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.26
Day's Low
0.2319
Volume
(Heavy Day)

Today's volume of 98,244 shares is on pace to be much greater than LTRY's 10-day average volume of 429,844 shares.

98,244

Evofem Partners with a360 Media to Support Phexxi(R) Prescription Growth

8:46 am ET July 21, 2022 (PR Newswire) Print

Agreement with a360 Media Delivers Phexxi Branded Content in Leading Entertainment and Lifestyle Magazines

a360 Media's Brands Include US Magazine, InTouch Weekly, and Woman's World

16% Lift in New Phexxi Prescriptions After First Two Weeks of Partnership

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced an agreement between Evofem and a360 Media under which Phexxi(R) (lactic acid, citric acid, and potassium bitartrate) branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S.

https://mma.prnewswire.com/media/780907/Evofem_Biosciences_Logo.jpg

"We are thrilled to partner with a360 Media to raise awareness of Phexxi among the millions of women reading some of the most popular magazines and websites in America," said Saundra Pelletier, Chief Executive Officer of Evofem.

a360 Media reaches 60 million unique digital visitors per month and another 27 million via print audiences. One out of every three a360 Media readers and digital users is a female between the ages of 18 and 34, making this partnership an ideal union. To date, 72% of the prescriptions through the Phexxi telehealth program are to women in this demographic.

After the first two weeks of the partnership, new prescriptions of Phexxi - a hormone-free, on-demand prescription contraceptive vaginal gel - were up 16%.

"Our magazine and digital brands are geared towards women looking for the latest on current events and information that can help them better their health and relationships," said Neil Goldstein, a360 Media's EVP, Chief Revenue Officer. "We are pleased to partner with Evofem to boost Phexxi's visibility with our readers, especially those women seeking hormone-free contraception, or those who are tired of the side effects they may be suffering from hormonal methods."

Three popular magazines featuring Phexxi content are on newsstands now, with more to come during the next several months.

About Evofem BiosciencesEvofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi(R) (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi(R) is a registered trademark of Evofem Biosciences, Inc.

Forward-Looking StatementsThis press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, evaluations and judgments regarding Evofem, its products, its product candidates and their development, demand for Evofem's products and product candidates, and the effectiveness or implied effectiveness of Evofem's efforts with a360 Media. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward- looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022 and its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Investor Relations ContactAmy RaskopfEvofem Biosciences, Inc.araskopf@evofem.com(917) 673-5775

Media Contactmedia@evofem.com

https://c212.net/c/img/favicon.png?sn=LA23400&sd=2022-07-21

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-partners-with-a360-media-to-support-phexxi-prescription-growth-301590824.html

SOURCE Evofem Biosciences, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=LA23400&Transmission_Id=202207210846PR_NEWS_USPR_____LA23400&DateId=20220721

comtex tracking

COMTEX_410670988/1005/2022-07-21T08:46:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.